Patents by Inventor Stefan M. Pulst
Stefan M. Pulst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240392290Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 1, 2024Publication date: November 28, 2024Applicant: University of Utah Research FoundationInventors: Stefan M. Pulst, Daniel R. Scoles, Sharan Paul
-
Publication number: 20240180953Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 31, 2023Publication date: June 6, 2024Applicant: University of Utah Research FoundationInventors: Stefan M. Pulst, Daniel R. Scoles, Sharan Paul
-
Patent number: 11946046Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.Type: GrantFiled: June 14, 2019Date of Patent: April 2, 2024Assignee: University of Utah Research FoundationInventors: Stefan M. Pulst, Daniel R. Scoles, Sharan Paul
-
Patent number: 11723912Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.Type: GrantFiled: December 8, 2017Date of Patent: August 15, 2023Assignee: University of Utah Research FoundationInventors: Stefan M. Pulst, Daniel R. Scoles, Sharan Paul
-
Publication number: 20210238590Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1-regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: June 14, 2019Publication date: August 5, 2021Applicant: University of Utah Research FoundationInventors: Stefan M. Pulst, Daniel R. Scoles, Sharan Paul
-
Publication number: 20200069721Abstract: Methods of minimizing dysregulation of Staufen1-associated RNA metabolism can include introducing an amount of a Staufen1 -regulating agent to a target cell sufficient to minimize the dysregulation. Therapeutic compositions for treating a neurodegenerative condition associated with Staufen1-induced dysregulation of RNA metabolism can include a therapeutically effective amount of a Staufen1-regulating agent and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 8, 2017Publication date: March 5, 2020Applicant: University of Utah Research FoundationInventors: Stefan M. Pulst, Daniel R. Scoles, Sharan Paul
-
Patent number: 10533178Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.Type: GrantFiled: May 7, 2018Date of Patent: January 14, 2020Assignees: Ionis Pharmaceuticals, Inc., University of Utah Research FoundationInventors: C. Frank Bennett, Susan M. Freier, Stefan M. Pulst, Daniel R. Scoles, Gene Hung
-
Publication number: 20190017047Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.Type: ApplicationFiled: May 7, 2018Publication date: January 17, 2019Applicants: Ionis Pharmaceuticals, Inc., University of Utah Research FoundationInventors: C. Frank Bennett, Susan M. Freier, Stefan M. Pulst, Daniel R. Scoles, Gene Hung
-
Patent number: 10006027Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism. Provided are methods for reducing expression of Ataxin 2 (ATXN2) mRNA and protein in an animal. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases, including spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism by inhibiting expression of Ataxin 2 in an animal.Type: GrantFiled: March 19, 2015Date of Patent: June 26, 2018Assignees: Ionis Pharmaceuticals, Inc., University of Utah Reseach FoundationInventors: C. Frank Bennett, Susan M. Freier, Stefan M. Pulst, Daniel R. Scoles, Gene Hung
-
Patent number: 9920333Abstract: Systems, constructs, and methods for reprogramming cells are provided. In one aspect, for example, a transformation construct for generating iPS cells can include an expression vector having a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter.Type: GrantFiled: December 30, 2015Date of Patent: March 20, 2018Assignee: University of Utah Research FoundationInventors: Stefan M. Pulst, Sharan Paul, Warunee Dansithong
-
Publication number: 20170175113Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism. Provided are methods for reducing expression of Ataxin 2 (ATXN2) mRNA and protein in an animal. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases, including spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism by inhibiting expression of Ataxin 2 in an animal.Type: ApplicationFiled: March 19, 2015Publication date: June 22, 2017Applicants: Ionis Pharmaceuticals, Inc., University of Utah Research FoundationInventors: C. Frank Bennett, Susan M. Freier, Stefan M. Pulst, Daniel R. Scoles, Gene Hung
-
Publication number: 20160222411Abstract: Systems, constructs, and methods for reprogramming cells are provided. In one aspect, for example, a transformation construct for generating iPS cells can include an expression vector having a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter.Type: ApplicationFiled: December 30, 2015Publication date: August 4, 2016Applicant: University of Utah Research FoundationInventors: Stefan M. Pulst, Sharan Paul, Warunee Dansithong
-
Patent number: 9228204Abstract: Systems, constructs, and methods for reprogramming cells are provided. In one aspect, for example, a transformation construct for generating iPS cells can include an expression vector having a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter.Type: GrantFiled: August 23, 2013Date of Patent: January 5, 2016Assignee: University of Utah Research FoundationInventors: Stefan M. Pulst, Sharan Paul, Warunee Dansithong
-
Patent number: 8975018Abstract: The present invention provides isolated nucleic acids encoding human SCA2 protein, or fragments thereof, and isolated SCA2 proteins encoded thereby. Further provided are vectors containing invention nucleic acids, probes that hybridize thereto, host cells transformed therewith, antisense oligonucleotides thereto and compositions containing antibodies that specifically bind to invention polypeptides, as well as transgenic non-human mammals that express the invention protein. In addition, methods for diagnosing spinocerebellar Ataxia Type 2 are provided.Type: GrantFiled: March 5, 2007Date of Patent: March 10, 2015Assignee: Cedars-Sinai Medical CenterInventor: Stefan M. Pulst
-
Publication number: 20140170752Abstract: Systems, constructs, and methods for reprogramming cells are provided. In one aspect, for example, a transformation construct for generating iPS cells can include an expression vector having a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter.Type: ApplicationFiled: August 23, 2013Publication date: June 19, 2014Applicant: University of Utah Research FoundationInventors: Stefan M. Pulst, Sharan Paul, Warunee Dansithong
-
Patent number: 8163483Abstract: Mutations in the KCNC3 (Kv3.3) voltage-gated potassium channel gene result in spinocerebellar ataxia.Type: GrantFiled: April 17, 2009Date of Patent: April 24, 2012Assignee: Cedars-Sinai Medical CenterInventor: Stefan M. Pulst
-
Patent number: 8138307Abstract: The invention provides parkin binding polypeptides and encoding nucleic acids. The invention also provides antibodies specific for the parkin binding polypeptides. The invention additionally provides methods of detecting a parkin binding polypeptide and detecting a nucleic acid encoding a parkin binding polypeptide. The invention further provides methods of using a parkin binding polypeptide. In one embodiment, the invention provides a method of identifying a candidate drug for treating Parkinson's disease by contacting a parkin binding polypeptide with one or more compounds and identifying a compound that alters the activity of the parkin binding polypeptide.Type: GrantFiled: February 18, 2004Date of Patent: March 20, 2012Assignee: Cedars-Sinai Medical CenterInventors: Stefan M. Pulst, Duong P. Huynh
-
Patent number: 7927786Abstract: The invention provides parkin binding polypeptides and encoding nucleic acids. The invention also provides antibodies specific for the parkin binding polypeptides. The invention additionally provides methods of detecting a parkin binding polypeptide and detecting a nucleic acid encoding a parkin binding polypeptide. The invention further provides methods of using a parkin binding polypeptide. In one embodiment, the invention provides a method of identifying a candidate drug for treating Parkinson's disease by contacting a parkin binding polypeptide with one or more compounds and identifying a compound that alters the activity of the parkin binding polypeptide.Type: GrantFiled: February 18, 2004Date of Patent: April 19, 2011Assignee: Cedars-Sinai Medical CenterInventors: Stefan M. Pulst, Duong P. Huynh
-
Publication number: 20090286243Abstract: Mutations in the KCNC3 (Kv3.3) voltage-gated potassium channel gene result in spinocerebellar ataxia.Type: ApplicationFiled: April 17, 2009Publication date: November 19, 2009Applicant: Cedars-Sinai Medical CenterInventor: Stefan M. Pulst
-
Patent number: 7585629Abstract: The autosomal dominant spinocerebellar ataxias (SCAs) represent a growing and heterogeneous clinical phenotype with ongoing discovery of causative etiologies. Methods: The authors collected DNA and clinically characterized a three-generation Filipino family segregating a dominant ataxia. Following elimination of several known SCA loci, a genome-wide linkage study was undertaken with additional fine mapping of 19q13. Results: Clinical characterization of affected family members revealed cerebellar signs including gait ataxia, limb ataxia/dysmetria, titubation, hypotonia, dysarthria, and nystagmus. Linkage was found in a ˜4 cM region of 19q13 bounded by markers D19S867 and D19S553, with a maximum LOD score of 3.89 at markers D19S904, D19S246, and D19S907. This region overlaps with, though markedly reduces the previously described SCA13 locus. Conclusion: An autosomal dominant cerebellar ataxia clinically distinguishable from SCA13 overlaps with the SCA13 locus on chromosome 19q13.3.Type: GrantFiled: April 24, 2006Date of Patent: September 8, 2009Assignee: Cedars-Sinai Medical CenterInventor: Stefan M. Pulst